LB929 Opioid use disorder in a cohort of hidradenitis suppurativa patients

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. While HS treatment consists of multi-tiered approach, many patients also seek therapy for debilitating pain. An increased risk long-term opioid use disorder (OUD) has been intensively explored in with HS; however, there paucity information associated ‘screening’ OUD. The Prescription Opioid Misuse Index (POMI), 6-point questionnaire, specific and sensitive instrument identifying All seen the Einstein/Montefiore Center (HSC) between September 1 December 31, 2021 were invited to participate this study. A total 66 volunteered complete telephone surveys. presence within cohort was evaluated POMI. Thirty participants (45%) reported taking prescription opioids HS-related Nineteen (63%) users female; 16 (53%) self-identified as Black/African American, 10 (33.3%) Spanish/Hispanic/Latino, 5 (17%) White, 1(3%) Asian. POMI questionnaire identified higher doses than prescribed; 4 (13%) reduced time doses; 6 (20%) early refills; described feeling “high” or “getting buzz” after using medication; 2 (7%) medication relieve cope problems other pain; went multiple physicians an emergency room, seeking more supplement original prescription. Overall, 7 (23%) pain that led prevalence substance disorder. More one every five pilot study screened positive Further screening OUD should be examined closely.